Previous studies, by this group and others, have shown that vasoactive intestinal peptide (VIP) stimulates aldosterone secretion, and that the actions of VIP on aldosterone secretion by the rat adrenal cortex are blocked by adrenergic antagonists, suggesting that VIP may act by the local release of catecholamines. The present studies were designed to test this hypothesis further, by measuring catecholamine release by adrenal capsular tissue in response to VIP stimulation.
Introduction
A range of neuropeptides is present in the rat adrenal cortex (for review see Vinson et al. 1994 , Toth & Hinson 1995 , Nussdorfer 1996 , Ehrhart-Bornstein et al. 1998 . Of these peptides vasoactive intestinal peptide (VIP) has been the most extensively studied. VIP has been shown to be present in nerves supplying the capsule and zona glomerulosa region of the adrenal gland (Hökfelt et al. 1981 , Holzwarth 1984 and has been shown to exert a significant influence on zona glomerulosa function. Prolonged infusion of VIP stimulates the growth and secretory capacity of the zona glomerulosa of rats and infusion of a VIP antagonist suppresses zona glomerulosa growth and secretory capacity (Rebuffat et al. 1994) . Experiments in vitro have given different results, depending on the tissue preparation used: it has been shown that VIP stimulates aldosterone secretion by rat adrenal capsular tissue (Cunningham & Holzwarth 1988) and by the intact perfused rat adrenal gland (Hinson et al. 1992 . However, experiments investigating the actions of VIP using dispersed zona glomerulosa cells from normal rats failed to demonstrate stimulation of aldosterone secretion (Enyedi et al. 1983 , Hinson et al. 1992 .
In 1992 we proposed an hypothesis to account for the differences in responsiveness of the different adrenal preparations (Hinson et al. 1992) . We proposed that VIP acts on islets of chromaffin cells, known to be present in the zona glomerulosa in the rat (Kovács & Horváth 1973 , Palacios & Lafraga 1975 , Gallo-Payet et al. 1987 ) and other species (for review see Nussdorfer 1996) , to stimulate the release of catecholamines, which then act on adrenal cells to stimulate aldosterone secretion. This hypothesis was supported by the observation that aldosterone secretion in response to VIP was attenuated in the presence of alprenolol, a adrenergic antagonist (Hinson et al. 1992) . Similar observations have subsequently been made by other groups (Mazzocchi et al. 1993 , Bernet et al. 1994 ), but to date no evidence has been presented to show a relationship between catecholamine release and aldosterone secretion. In addition, the possibility that adrenergic antagonists might alter VIP binding to its receptor has not been investigated.
The present studies were designed to investigate the actions of VIP and catecholamines on zona glomerulosa function. These studies have employed both normal rats, and rats fed a low sodium diet, as there is evidence that the adrenal response to VIP is altered following dietary sodium depletion (Hinson & Kapas 1995) . We have investigated the effects of VIP on catecholamine release by adrenal capsular tissue, and we have used ligand binding studies to investigate the specificity of VIP binding to the zona glomerulosa. 
Materials and Methods

Materials
Sodium depletion of animals
Male and female Wistar rats (250-400 g body weight), supplied by A Tuck & Sons, Battlesbridge, Essex, UK and maintained at Queen Mary and Westfield College, were used. Animals were depleted of sodium, as previously described (Fattah et al. 1978) by feeding them a diet of wholemeal flour supplemented with 100 nmol calcium carbonate/kg for a minimum period of 21 days, with access to distilled water. Control animals were fed the same diet with the addition of 170 mmol sodium chloride/ kg. These experiments were authorised by Home Office project licence number 70/00063.
Preparation of rat adrenal capsules
The rats were stunned and then killed by cervical dislocation. Adrenals were rapidly removed and cleaned of adhering fat. Capsule fractions (with mainly glomerulosa cells attached) were separated from inner adrenocortical tissue by pressure between glass plates. Capsules were preincubated in Krebs bicarbonate Ringer containing glucose (200 mg/100 ml) (KRBG) for 1 h at 37 C under an atmosphere of 95% O 2 and 5% CO 2 . After preincubation capsules were incubated in fresh KRBG for 1 h under an atmosphere of 95% O 2 and 5% CO 2 in the absence or presence of stimulants inhibitors.
Effect of agonists inhibitors on steroidogenesis
All peptides were dissolved in KRBG to the required concentrations. A range of concentrations of VIP, from 10 10 mol/l to 10 6 mol/l were used. In other experiments, to test the action of antagonists on VIP-stimulated aldosterone secretion, capsules were incubated with various concentrations of VIP in the presence of 10 7 mol/l antagonist for 1 h. After incubation, the capsules were discarded and half the incubation media were placed into clean microfuge tubes and the tubes stored at 20 C until the media were assayed for aldosterone. Aldosterone was measured in an aliquot of unextracted incubation medium by direct radioimmunoassay (RIA; Kapas et al. 1992) . A small volume of acetic acid was added to the remaining incubation media (final concentration 10%, v/v) and the media assayed for catecholamines.
Catecholamine assay
The assay of adrenaline and noradrenaline is based on the trihydroxyindole fluorescence method of Brocklehurst & Pollard (1990) . The technique involves the oxidation of catecholamines by K 2 Fe(CN) 6 and the subsequent generation of the trihydroxyindole fluorophore product by NaOH and ascorbic acid. The oxidation reactions are performed under both acidic and neutral pH conditions to allow measurement of adrenaline and noradrenaline. Briefly, assays were carried out as follows. To one set of 50 µl samples 500 µl 0·5 mol/l sodium phosphate buffer (pH 7·0) were added. To another (identical) set of samples 500 µl 10% (v/v) acetic acid were added. All samples received 50 µl K 2 Fe(CN) 6 and were incubated on ice for 20 min. The reactions were terminated with 1 ml 9 mol/l NaOH containing 0·4% ascorbic acid (w/v), followed by vigorous vortexing. After the addition of 2 ml water, the trihydroxyindole fluorescence product was measured in a spectrofluorimeter (Luminescent fluorimeter LS-50B, Perkin Elmer, Warrington, Lancs, UK) with an excitation wavelength of 412 nm and an emission wavelength of 523 nm.
Receptor binding assay
The binding assay was carried out as previously described (Kapas et al. 1996) . Rat adrenal capsules were prepared as described above. After incubation, capsules were homogenised in 150 mmol/l Tris-HCl buffer (pH 7·6) containing 1 µg/ml each of aprotinin and soybean trypsin inhibitor. Homogenates were centrifuged at 800 g for 10 min and the supernatant re-centrifuged at 100 000 g for 1 h. The particulate (membrane) fraction was then resuspended in Tris-HCl buffer containing 100 mmol/l NaCl, 6 mmol/l MgCl 2 , 0·1% (w/v) BSA and protease inhibitors (1ug/ml each of soybean trypsin inhibitor and aprotinin).
Aliquots of membrane suspension (100 µg protein/tube) were incubated with 3-( 125 I-iodotyrosyl 10 )VIP (2000 Ci/ mmol; final concentration 0·1 nmol/l) with increasing concentrations of unlabelled VIP, PL-VIP, atenolol, ICI 118 551, angiotensin II and adrenocorticotrophic hormone (ACTH) (0·39-50 nmol/l). Non-specific binding was determined by incubating labelled cells with 100-fold excess of unlabelled VIP. Incubations were terminated by the addition of 800 µl ice-cold buffer and the tubes were centrifuged at 10 000 g for 5 min at 4 C. Supernatants were discarded and the pellets washed twice. After washing, radioactivity bound to the membrane was estimated using a 1272 Clinigamma counter (LKB Wallac, St Albans, Herts, UK). Binding studies were repeated at least three times.
Statistical analysis
Arithmetic means and ... values were calculated. One-way analysis of variance was used to test whether VIP had a significant effect on basal (control) levels of aldosterone or catecholamine release as appropriate. Student's t-tests were used to test whether the abovementioned responses were affected by the presence of antagonists. Saturation data were analysed by LIGAND (Munson & Rodbard 1980 ). Student's t-tests were also used to test whether the responses of the sodium-depleted group were significantly different to those of the control diet group.
Results
VIP was found to cause a dose-dependent increase in both aldosterone and catecholamine secretion by rat adrenal capsular tissue in vitro (Fig. 1) . Release of both adrenaline and noradrenaline was observed, with the increase in adrenaline seen in parallel with aldosterone secretion. The minimum concentration of VIP required for significant stimulation of aldosterone and adrenaline was 1 nmol/l, although 10 nmol/l were required for significant noradrenaline secretion. The effects of VIP on aldosterone secretion were inhibited by the 1 antagonist, atenolol (100 nmol/l), but not by ICI 118 551, a 2 antagonist (Fig.  2) . The effects of VIP were totally specific to the zona glomerulosa: there was no effect of VIP on corticosterone release by inner zone tissue (data not shown).
Ligand binding studies revealed a single population of VIP receptors in both control and the low sodium animals (Fig. 3) . The Hill coefficient for the control group was 0·908, and for the low sodium group 0·925. The VIP receptors from both groups were found to have a similar K d : 2·26 0·45 nmol/l in the control group and 1·62 0·32 nmol/l in the low sodium group. While the low sodium group had a higher number of binding sites than the controls (944 153 vs 853 101 fmol/mg protein), this difference was not statistically significant. Displacement studies showed that VIP binding to homogenates of adrenal capsules from the control or low sodium group was not significantly displaced by ACTH, angiotensin II, atenolol or ICI 118 551 (Table 1) .
In adrenal capsular tissue obtained from sodiumdepleted animals VIP significantly stimulated aldosterone secretion (Fig. 4) . The basal level of aldosterone secretion was considerably greater in the sodium-depleted adrenals compared with the controls. In the capsules from sodiumdepleted animals VIP also significantly stimulated the release of adrenaline and noradrenaline (Fig. 5 ). There were no significant differences between levels of catecholamine release, either basal or stimulated, in the sodiumdepleted group compared with the controls. However, in the sodium-depleted adrenal capsules the aldosterone response to VIP stimulation was not attenuated by atenolol (Fig. 4) . 
Figure 4
The 1 adrenergic antagonist, atenolol (100 nmol/l: hatched bars), had no effect on the aldosterone response to VIP (100 nmol/l) in adrenals obtained from animals maintained on a low sodium diet. Values are means S.E.M. (n=6).
Discussion
The results presented clearly demonstrate that VIP had a dose-dependent effect on the release of catecholamines from adrenal capsular tissue. The release of adrenaline, but not noradrenaline, was found to parallel the increase in aldosterone secretion. The ratio of adrenaline/ noradrenaline found in this study is consistent with that previously reported in rat adrenal capsules and in the rat adrenal medulla (Pratt et al. 1985) . Presumably the catecholamines are derived from the islets of chromaffin cells reported to be present in the zona glomerulosa region of the adrenal cortex (Kovács & Horváth 1973 , Palacios & Lafraga 1975 , Gallo-Payet et al. 1987 , as the adrenal capsules were separated from the adrenal medulla in these experiments. It is, however, possible that noradrenaline may be released from nerve terminals remaining in the separated capsular tissue. It is well established that VIP stimulates catecholamine release from adrenal medullary chromaffin cells (Malhotra & Wakade 1987 , Wakade et al. 1991 . In this study it was found that the release of adrenaline in response to VIP displayed the same doseresponse characteristics, supporting the contention that local catecholamine release mediates the response to VIP in this tissue. Most previous studies, investigating the possible role of catecholamines in the aldosterone response to VIP stimulation, have failed to demonstrate release of catecholamines in response to VIP, although we have published some preliminary data (Hinson et al. 1992 (Hinson et al. , 1996 . Instead, most attention has been focussed on the effects of adrenergic antagonists, specifically alprenolol and propranolol, nonselective adrenergic antagonists, and atenolol, a selective 1 antagonist. These agents have been found to significantly inhibit the response of the zona glomerulosa of both rat and human adrenals to VIP stimulation (Mazzocchi et al. 1993 , Bernet et al. 1994 , Bornstein et al. 1996 . In the absence of data on either catecholamine release, or on VIP binding, the mechanism of action of these agents has remained speculative. As previous studies have shown that neuropeptide Y interacts with adrenoceptors (Martire & Pistritto 1992) , this appeared to be a possible mechanism of the inhibitory action of adrenergic antagonists on VIP stimulation of aldosterone secretion. The data obtained in the present study, however, clearly demonstrating release of catecholamines in response to VIP, together with the observed specificity of the VIP binding, supports the hypothesis that adrenergic antagonists inhibit the aldosterone response to VIP by blocking the action of catecholamines released in response to VIP stimulation.
The question as to whether the catecholamines are able to influence aldosterone secretion was not directly addressed by the present study, as there is already much evidence to support the contention that adrenergic agonists stimulate aldosterone secretion in a variety of different rat adrenal preparations, including adrenal slices (Andreis et al. 1995) , capsular preparations in vitro (Shima et al. 1984 , Pratt et al. 1985 , Pratt & McAteer 1989 , the isolated perfused adrenal preparation ( J P Hinson, unpublished observations) and dispersed zona glomerulosa cell preparations (Horiuchi et al. 1987) . The question of the physiological role of the VIP-catecholamine system in the regulation of zona glomerulosa function remains unclear.
It has been suggested that the effects of VIP in the adrenal gland are mediated in part via the ACTH receptor (Li et al. 1990 . This suggestion was originally made following the observation that VIP displaced binding of labelled ACTH from a subpopulation of ACTH receptors (Li et al. 1990 ) and was restated on the basis that corticotrophin inhibitory peptide was shown to attenuate the rat adrenal response to VIP stimulation . Data from the present studies do not support this contention: a single population of VIP binding sites was identified in the zona glomerulosa, and only VIP and its specific antagonist (PL-VIP) were found to displace binding of labelled VIP. Neither ACTH, angiotensin II nor the adrenergic antagonists were found to displace labelled VIP, suggesting that the zona glomerulosa expresses a single population of VIP receptors. We have not investigated the possibility that ACTH may interact with the specific VIP receptors identified in the adrenal cortex, although this possibility may partly explain the observations of Li and coworkers (1990) . This study did not address the question as to which of the VIP receptor subtypes (for review see Harmar et al. 1998) are present in the rat zona glomerulosa and mediate the actions of VIP in this tissue, but the binding studies suggest that only one receptor subtype is present.
We have previously observed an increase in adrenal VIP content in animals maintained on a low sodium diet, raising the possibility that locally produced VIP has a role in the adrenal response to perturbed electrolyte balance (Hinson et al. 1996) . We also reported an increase in the adrenal responsiveness to VIP following dietary sodium depletion, such that aldosterone secretion was significantly stimulated by a lower concentration of VIP in the low sodium group compared with controls (Hinson & Kapas 1995) , and proposed that the zona glomerulosa expresses a distinct population of VIP receptors in response to changes in electrolyte balance. The results of the present study do not support this proposal: it was found that adrenals from the low sodium group of animals expressed a population of VIP receptors with the same K d as controls, and with only a marginally greater B max , which was not significantly different from controls.
One of the most interesting observations made in the present study was that the aldosterone response of adrenals from the low sodium group was not attenuated by the adrenergic antagonist, atenolol, although catecholamine release was elevated by VIP to the same extent as in the control group. It is not clear why atenolol had no effect in this group, although it is possible that a different subtype of adrenergic receptor is expressed in the adrenals of animals maintained on a low sodium diet. However, the data obtained in the present study suggest that it is not the 2 subtype of adrenoceptor and other studies have found that activation of adrenoceptors in the rat adrenal cortex inhibits aldosterone secretion (Lotshaw et al. 1991) so this is most unlikely to be the mechanism by which VIP exerts its stimulatory effects in this group. Clearly this requires further study.
In conclusion, these data suggest that VIP stimulates aldosterone secretion indirectly via release of catecholamines. There appear to be different mechanisms mediating the actions of VIP in animals fed a low sodium diet compared with controls, but the nature of these mechanisms is not yet clear. The physiological significance of a VIP-catecholamine system in the regulation of aldosterone secretion also remains unclear. Hinson JP, Ho MM, Vinson GP & Kapas S 1996 
